Menéndez CRL

Language: Spanish
References: 18
Page: 62-79
PDF size: 288.69 Kb.

ABSTRACT

Malaria is a potentially fatal acute febrile disease caused by parasites of the genus Plasmodium, transmitted to humans by the bite of female mosquitoes of the genus Anopheles infected by Plasmodium species. At the close of 2016, two hundred fourteen million people were infected worldwide, most of them in Sub-Saharan Africa. Early diagnosis and treatment of malaria lessen the incidence of the disease, reduce its fatal effects and contribute to prevent its transmission. The best therapeutic option available, especially for P. falciparum malaria, is combined treatment with artemisin. The purpose of the study was to identify the basic aspects to consider in the suppression treatment of malaria, thus contributing to reduce its morbidity and mortality. Analysis was based not only on the bibliography consulted, but also on the experience accumulated by the author during his eight years of work in endemic areas and more than thirty years as a professor of master's degree programs and infectology courses at Pedro Kourí Tropical Medicine Institute. It is concluded that hematic schizonticides lie at the core of any antimalarial treatment, particularly those derived from artemisin used in combined therapy schemes for critically ill and uncomplicated resistant patients.

REFERENCES

1. OPS/OMS. Guía para la atención clínica integral del paciente con malaria. No. 256-237, Bogotá: Convenio de Cooperación Técnica con el Ministerio de la Protección Social; 2010.

2. Organización Mundial de la Salud. Paludismo. Ginebra: OMS; Nota descriptiva 11 Junio de 2018. [citado 14 Jul 2018]. Disponible en: http://www.who.int/es/newsroom/ fact-sheets/detail/malaria

3. Organización Mundial de la Salud. Paludismo. Ginebra: OMS; Temas de salud 2016. [citado 14 Jun 2016]. Disponible en: http://www.who.int/topics/malaria/es/

4. Organización Mundial de la Salud. Paludismo: información para viajeros. Ginebra: OMS; International Travel and Health 2017. [citado 14 Jun 2018]. Disponible en: http://www.who.int/ith/2017-ith-chapter7.pdf?ua=1

5. OMS. Guidelines for the treatment of malaria, 2da ed. Suiza: OMS; 2010. 207 p.

6. Likwela JL, D'Alessandro U, Lokwa BL, Meuris S, Dramaix MW. Sulfadoxinepyrimethamine resistance and intermittent preventive treatment during pregnancy: a retrospective analysis of birth weight data in the Democratic Republic of Congo (DRC). Trop Med Int Health. 2012 Mar;17(3):322-9.

7. Ferrer MR, Muñoz LL, Tamayo JMA. Paludismo en niños. Multimed [Internet] 2010. [citado 19 May 2017];14(4):[aprox. 11 p.] Disponible en: http://www.multimedgrm.sld.cu/articulos/2010/v14-4/10.html

8. Organización Mundial de la Salud. Tratamiento del paludismo. Ginebra: OMS; Actualización 26 Ene 2018. [citado 14 Jun 2018]. Disponible en: http://www.who.int/malaria/areas/treatment/overview/es/

9. Muñoz J, Rojo G, Ramírez G, Salas J, Treviño B, Pérez JL, et al. Diagnóstico y tratamiento de la malaria importada en España: recomendaciones del Grupo de Trabajo de Malaria de la Sociedad Española de Medicina Tropical y Salud Internacional (SEMTSI). Enferm Infecc Microbiol Clín. 2015;33(6):1-13.

10. Organización Mundial de la Salud. Epidemias de paludismo y emergencias. Ginebra: OMS; [actualizado 22 Ene 2018; citado 22 Jun 2018]. Disponible en: http://www.who.int/malaria/areas/epidemics_emergencies/es/

11. Stauffer W. Malaria. En Frank J. Domino ed. The 5 minute clinical consult standard 2011. [CD-ROM]. 19a ed. Philadelphia: Lippincott Williams & Wilkins/ Wolters Kluwer Health; 2010.

12. Salvadó E, Pinazo MJ, Muñoz J, Alonso D, Naniche D, Mayor A, et al. Presentación clínica y complicaciones de malaria importada por Plasmodium falciparum en dos grupos de población: viajeros e inmigrantes. Enferm Infecc Microbiol Clín. 2008;26(5):282-4.

13. Tobón A. Signos de peligro en el paciente con malaria. A Biomédica. 2009;29:320-9.

14. Tshefu AK, Gaye O, Kayentao K, Thompson R, Bhatt KM, Sesay SS, et al. Pyronaridine-artesunate Study Team. Efficacy and safety of a fixed-dose oral combination of pyronaridine-artesunate compared with artemether-lumefantrine in children and adults with uncomplicated Plasmodium falciparum malaria: a randomized non-inferiority trial. Lancet. 2010;375(9724):1457-67.

15. Weiss WR, Oloo AJ, Johnson A, Koech D and Hoffman SL. Daily Primaquine Is Effective for Prophylaxis against Falciparum Malaria in Kenya: Comparison with Mefloquine, Doxycycline, and Chloroquine plus Proguanil. J Infect Dis. 1995;171(6):1569-75.

16. White NJ. The role of anti-malarial drugs in eliminating malaria. Malar J. 2008;7(Supl 1):S1-8.

17. Majori G. Combined antimalarial therapy using artemisinin. Parasitologia. 2004 Jun;46(1-2):85-7.

18. Naing C, Mak JW, Aung K, Wong JY. Efficacy and safety of dihydroartemisininpiperaquine for treatment of uncomplicated Plasmodium falciparum malaria in endemic countries: meta-analysis of randomized controlled studies. Trans R Soc Trop Med Hyg. 2013 Feb;107(2):65-73.